⏳ Fetching live dividend data...
Home › Calculator › DIUXF Dividend Calculator 2026
Diaceutics PLC · OTC
Price: $1.67 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in DIUXF → $13.48M in 10 years · $3,400.12/month
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open DIUXF position with:
Real after-tax yield depends on where you live and how you hold DIUXF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 119.76% | 116.96% | $11,976 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 101.80% | 99.00% | $10,180 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 95.81% | 93.01% | $9,581 / yr |
| 🇬🇧 UK ISA | 0% | 119.76% | 116.96% | $11,976 / yr |
| 🇬🇧 UK Taxable | 8.75% | 109.28% | 106.48% | $10,928 / yr |
| 🇨🇦 TFSA | 0% | 119.76% | 116.96% | $11,976 / yr |
| 🇨🇦 CA Taxable | 25% | 89.82% | 87.02% | $8,982 / yr |
| 🇦🇺 Super (pension) | 15% | 101.80% | 99.00% | $10,180 / yr |
| 🇦🇺 AU Taxable | 30% | 83.83% | 81.03% | $8,383 / yr |
| 🇩🇪 DE Taxable | 26.375% | 88.17% | 85.37% | $8,817 / yr |
| 🇫🇷 FR Taxable | 30% | 83.83% | 81.03% | $8,383 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
DIUXF pays quarterly — 4 times per year. Next ex-div: TBD.
How DIUXF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for DIUXF sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the DIUXF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →